Genome-wide cell-free DNA methylation analyses improve accuracy of non-invasive diagnostic imaging for early-stage breast cancer

Presented by: Reza Khayami



Breast cancer

The most common cancer in women worldwide.

Detection:

- Mammogram
- Ultrasound

routinely administered to detect early BC in asymptomatic females, but prone to underestimation or over-diagnosis



BI- RADS ASSESSMENT CATEGORIES

	Category	Recommended Action	Likelihood of Cancer
0	Incomplete	Need additional views / imaging to further evaluate	N/A
1	Negative	Continue routine annual screening	Essentially 0%
2	Probably benign	Continue routine annual screening	Essentially 0%
3	Benign	Short interval follow-up suggested (6 months)	<2% probability of malignancy
4	Suspicious for malignancy	Biopsy should be considered	 * 4A: low suspicion for malignancy (2-9%) * 4B: moderate suspicion for malignancy (10-49%) * 4C: high suspicion for malignancy (50-94%)
5	Highly suggestive of malignancy	Biopsy required	Proven malignancy
6	Known biopsy-proven malignancy	Confirmed biopsy and treatment planning	>95% probability of malignancy






Why methylation?


The lack of multiple common mutations in BC has limited the sensitivity of mutation-based ctDNA detection

Combining liquid biopsy with diagnostic imaging




Breast CANCER






















Methylation markers

- four functional genes (RYR2, RYR3, GABRB3, and DCDC2C)
- two IncRNAs (AC096570.1 and LINC00923)







Thank you

"Life is 10% what happens to us and 90% how we react to it." — Leslie Medley-Russell, two times ovarian cancer survivor